Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study
- PMID: 16998946
- DOI: 10.1002/pds.1297
Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study
Abstract
Background: There is considerable evidence that statins can reduce cardiovascular events. Currently high-risk patients are treated to a target cholesterol concentration. An alternative prescribing strategy (the 'fire-and-forget' approach) would instead deploy low-dose statins more widely. It has been suggested that for the same cost this approach might prevent more cardiovascular events. We have compared the treat-to-target and fire-and-forget statin prescribing strategies with respect to adherence and cardiovascular outcomes.
Methods: We used a population-based record-linkage database containing several data sets linked by a unique patient identifier. We identified two cohorts of patients. Patients in the treat-to-target cohort were prescribed a statin, and subsequent measurement of their cholesterol was followed by upward titration of their statin dose if necessary. Patients in the fire-and-forget cohort were prescribed a statin, but no further cholesterol measurement was observed during the follow-up period.
Findings: Adherence to statin treatment in patients treated to target was significantly better than in patients treated on a fire-and-forget basis (adjusted odds ratio 2.51, 95%CI 2.26-2.78). We found a lower cardiovascular disease (CVD) event rate in patients treated to target than in fire-and-forget patients (hazard ratio of CVD or cardiovascular death 0.41 (0.35-0.48) even after adjustment was made for adherence and baseline CVD risk).
Interpretation: Our findings suggest that adherence to statins is worse in patients treated on a fire-and-forget basis than in patients treated to a target cholesterol concentration, and that this prescribing strategy is associated with worse cardiovascular outcomes.
Similar articles
-
[Lipid-lowering therapy and patient adherence in the MULTI GAP 2013 trial].Orv Hetil. 2014 Apr 27;155(17):669-75. doi: 10.1556/OH.2014.29905. Orv Hetil. 2014. PMID: 24755449 Hungarian.
-
Audit-based education to reduce suboptimal management of cholesterol in primary care: a before and after study.J Public Health (Oxf). 2006 Dec;28(4):361-9. doi: 10.1093/pubmed/fdl052. Epub 2006 Oct 11. J Public Health (Oxf). 2006. PMID: 17038329
-
Effects of Race on Statin Prescribing for Primary Prevention With High Atherosclerotic Cardiovascular Disease Risk in a Large Healthcare System.J Am Heart Assoc. 2019 Nov 19;8(22):e014709. doi: 10.1161/JAHA.119.014709. Epub 2019 Nov 11. J Am Heart Assoc. 2019. PMID: 31707943 Free PMC article.
-
Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.Cochrane Database Syst Rev. 2018 Nov 19;11(11):CD012502. doi: 10.1002/14651858.CD012502.pub2. Cochrane Database Syst Rev. 2018. PMID: 30480766 Free PMC article.
-
Interventions to Improve Statin Tolerance and Adherence in Patients at Risk for Cardiovascular Disease : A Systematic Review for the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Management of Dyslipidemia.Ann Intern Med. 2020 Nov 17;173(10):806-812. doi: 10.7326/M20-4680. Epub 2020 Sep 22. Ann Intern Med. 2020. PMID: 32956601
Cited by
-
How patient cost-sharing trends affect adherence and outcomes: a literature review.P T. 2012 Jan;37(1):45-55. P T. 2012. PMID: 22346336 Free PMC article.
-
Familial hypercholesterolemia--screening to facilitate early prevention.Dtsch Arztebl Int. 2014 Aug 4;111(31-32):521-2. doi: 10.3238/arztebl.2014.0523. Dtsch Arztebl Int. 2014. PMID: 25145509 Free PMC article. No abstract available.
-
'Real-life' reduction in cholesterol with statins, 1993 to 2002.Br J Clin Pharmacol. 2008 Apr;65(4):587-92. doi: 10.1111/j.1365-2125.2007.03066.x. Epub 2008 Jan 30. Br J Clin Pharmacol. 2008. PMID: 18241286 Free PMC article.
-
Recognizing and improving patient nonadherence to statin therapy.Curr Atheroscler Rep. 2008 Feb;10(1):19-24. doi: 10.1007/s11883-008-0004-4. Curr Atheroscler Rep. 2008. PMID: 18366981 Review.
-
[Update lipidology : Evidence-based treatment of dyslipidemia].Inn Med (Heidelb). 2023 Jul;64(7):611-621. doi: 10.1007/s00108-023-01536-8. Epub 2023 Jun 15. Inn Med (Heidelb). 2023. PMID: 37318557 Free PMC article. Review. German.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical